Rager-Zisman Bracha
Department of Microbiology Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, POB 653, 84105 Beer Sheva, Israel.
Perspect Biol Med. 2012;55(4):590-607. doi: 10.1353/pbm.2012.0043.
Synthetic biology is a relatively new science with tremendous potential to change how we view and know the life sciences, but like many developing technologies, it has provoked ethical concerns from the scientific community and the public and confronts demands for new regulatory measures. The concerns raised involve the danger of "dual use," in which results for improving human well-being and the environment may be misappropriated for bioterror. To counteract these dangers, many governments, but the United States and Israel in particular, have introduced new laws and redoubled measures for biosafety and biosecurity. In the United States, the recent H5N1 results achieved by two groups of NIH-funded investigators highlighted the dilemma of balancing the risk of dual-use research and the freedom of science. In Israel, concern for unconventional terrorism is long-standing, and the country is constantly engaged in improving biosecurity and biodefense measures. In 2008, the Israeli parliament passed the Regulation of Research into Biological Disease Agents Law, a legislative framework for safeguarding research into biological disease agents. This article summarizes and analyzes the current state of affairs in the United States and Israel, ethical attitudes, and regulatory responses to synthetic biology.
合成生物学是一门相对较新的科学,具有极大潜力改变我们看待和认识生命科学的方式,但与许多新兴技术一样,它引发了科学界和公众的伦理担忧,并面临着对新监管措施的要求。引发的担忧涉及“两用”风险,即改善人类福祉和环境的成果可能被滥用于生物恐怖活动。为应对这些风险,许多国家政府,尤其是美国和以色列,出台了新法律并加倍采取生物安全和生物安保措施。在美国,国立卫生研究院资助的两组研究人员近期取得的H5N1研究成果凸显了平衡两用研究风险与科学自由的困境。在以色列,对非常规恐怖主义的担忧由来已久,该国不断致力于改进生物安保和生物防御措施。2008年,以色列议会通过了《生物致病因子研究监管法》,这是一项保障生物致病因子研究的立法框架。本文总结并分析了美国和以色列的现状、伦理态度以及对合成生物学的监管应对措施。